PHAIM AIM ANTIGENIC IMMUNE MODULATION
LIVE

Serial Number

90770788

Owner

Phaim Pharma Ltd.

Attorney

Joseph L. Morales

Filing Date

Jun 12, 2021

Add to watchlist:

No watchlists yet
View on USPTO

PHAIM AIM ANTIGENIC IMMUNE MODULATION Trademark

Serial Number: 90770788 • Registration: 6842815

PHAIM AIM ANTIGENIC IMMUNE MODULATION is a trademark filed by Phaim Pharma Ltd. on June 12, 2021. The trademark is classified under Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 44 (Medical Services), Class 35 (Advertising & Business). The application is currently registered and active.

Owner Contact Info

Phaim Pharma Ltd. (3 trademarks)

One Bartholomew Close
London EC1A7BL , GB

Entity Type: 99

Trademark Details

Filing Date

June 12, 2021

Registration Date

September 13, 2022

Published for Opposition

June 28, 2022

Goods & Services

Vaccines; Chemical preparations for the diagnosis of diabetes; Pharmaceutical preparations for the prevention of diabetes; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for the prevention of diseases of the immune system; Pharmaceutical preparations for the prevention of disorders of the immune system; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of autoimmune diseases; Pharmaceutical preparations for the prevention of autoimmune diseases; Pharmaceutical preparations for the treatment of autoimmune disorders; Pharmaceutical preparations for the prevention of autoimmune disorders; Pharmaceutical preparations for regulating the immune system; Pharmaceutical preparations; Chemical preparations for medical purposes

Advertising services relating to pharmaceuticals for the treatment of diabetes; Advertising services relating to pharmaceuticals; Advertising, marketing and promotional services; Advertising; Compilation of statistical data for use in scientific research; Compilation of statistical data relating to medical research; Advertising services to promote public awareness of medical conditions; Advertising services related to immune disorders; Advertising services related to autoimmune diseases

Diabetes screening services; Medical services in the field of diabetes; Providing information via the Internet in the field of diabetes; Medical screening; Health screening services; Medical analysis services for diagnostic and treatment purposes provided by medical laboratories; Medical services for the diagnosis of conditions of the human body; Medical services; Medical diagnostic services; Medical services for the treatment of conditions of the human body; Medical testing services relating to the diagnosis and treatment of disease; Performing diagnosis of diseases; Medical information services provided via the Internet; Providing medical information; Medical analysis services for autoimmune disease diagnosis and prognosis

Medical test kits for diabetes monitoring for home use; Testing instruments for medical diagnostic purposes; Blood glucose testing apparatus; Apparatus for carrying-out diagnostic tests for medical purposes; Diagnostic, examination, and monitoring equipment; Medical apparatus for testing the level of glucose in the blood; Medical apparatus and instruments; Medical diagnostic instruments; Medical testing instruments

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Sep 13, 2022 NRCC
REGISTERED-PRINCIPAL REGISTER
Sep 13, 2022 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jun 28, 2022 NPUB
PUBLISHED FOR OPPOSITION
Jun 28, 2022 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jun 8, 2022 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
May 21, 2022 CNSA
EXAMINER'S AMENDMENT ENTERED
May 15, 2022 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
May 15, 2022 GNEN
EXAMINERS AMENDMENT E-MAILED
May 15, 2022 GNEA
EXAMINERS AMENDMENT -WRITTEN
May 15, 2022 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 11, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 11, 2022 CRFA
ASSIGNED TO LIE
Mar 9, 2022 ALIE
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Mar 7, 2022 ERSI
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Mar 3, 2022 GNS3
LETTER OF SUSPENSION E-MAILED
Mar 3, 2022 GNSL
SUSPENSION LETTER WRITTEN
Mar 3, 2022 CNSL
ASSIGNED TO EXAMINER
Mar 3, 2022 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 1, 2021 NWOS
NEW APPLICATION ENTERED
Jun 16, 2021 NWAP